Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.
作者信息
Gautret Philippe, Lagier Jean-Christophe, Honoré Stéphane, Hoang Van Thuan, Colson Philippe, Raoult Didier
机构信息
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
出版信息
Int J Antimicrob Agents. 2021 Jan;57(1):106243. doi: 10.1016/j.ijantimicag.2020.106243.
Abstract
摘要
相似文献
1
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.羟氯喹和阿奇霉素用于治疗新型冠状病毒肺炎：重新审视一项开放标签非随机临床试验的结果
Int J Antimicrob Agents. 2021 Jan;57(1):106243. doi: 10.1016/j.ijantimicag.2020.106243.
2
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.羟氯喹啉和阿奇霉素治疗新型冠状病毒肺炎的临床疗效及安全性概况
Int J Antimicrob Agents. 2021 Jan;57(1):106242. doi: 10.1016/j.ijantimicag.2020.106242.
3
Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.羟氯喹啉与阿奇霉素联合治疗COVID-19患者的安全性概况。
Int J Antimicrob Agents. 2021 Jan;57(1):106236. doi: 10.1016/j.ijantimicag.2020.106236.
4
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.羟氯喹和阿奇霉素对新型冠状病毒肺炎患者严重急性呼吸综合征冠状病毒2清除率的影响：一项荟萃分析
Int J Antimicrob Agents. 2021 Jan;57(1):106240. doi: 10.1016/j.ijantimicag.2020.106240.
5
Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.用于2019冠状病毒病诊断的严重急性呼吸综合征冠状病毒2聚合酶链反应结果解读
Int J Antimicrob Agents. 2021 Jan;57(1):106238. doi: 10.1016/j.ijantimicag.2020.106238.
6
Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.羟氯喹和阿奇霉素治疗COVID-19的效果：一项开放标签非随机临床试验的结果，意向性分析及临床结局的更新
Int J Antimicrob Agents. 2021 Jan;57(1):106239. doi: 10.1016/j.ijantimicag.2020.106239.
7
Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.羟氯喹治疗新型冠状病毒肺炎的疗效评估：一项开放标签非随机临床试验的二次分析
Int J Antimicrob Agents. 2021 Jan;57(1):106172. doi: 10.1016/j.ijantimicag.2020.106172.
8
Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.参考研究：《羟氯喹和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果》
Int J Antimicrob Agents. 2021 Jan;57(1):106176. doi: 10.1016/j.ijantimicag.2020.106176.
9
Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".致编辑的信：关于“羟氯喹和阿奇霉素作为治疗新型冠状病毒肺炎的药物：一项开放标签非随机临床试验的结果”
Int J Antimicrob Agents. 2021 Jan;57(1):106171. doi: 10.1016/j.ijantimicag.2020.106171.
10
Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".关注“羟氯喹和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果”的临床结局。
Int J Antimicrob Agents. 2021 Jan;57(1):106175. doi: 10.1016/j.ijantimicag.2020.106175.
引用本文的文献
1
Association and Interaction of Epstein-Barr Virus with SARS-CoV-2 Infection-A Review.爱泼斯坦-巴尔病毒与严重急性呼吸综合征冠状病毒2感染的关联及相互作用——综述
Viruses. 2025 Jun 26;17(7):903. doi: 10.3390/v17070903.
2
The COVID-19 pandemic transformed this scientist into a research-integrity sleuth.新冠疫情将这位科学家变成了一名科研诚信侦探。
Nature. 2025 Jul 22. doi: 10.1038/d41586-025-01920-4.
3
Inaugural Lifestyle Medicine Editorial: Lifestyle medicine in the time of COVID-19.生活方式医学创刊社论：新冠疫情时代的生活方式医学
Lifestyle Med (Hoboken). 2020 Jul;1(1):e1. doi: 10.1002/lim2.1. Epub 2020 Jun 11.
4
Potential Drugs in COVID-19 Management.新冠病毒管理中的潜在药物。
Curr Med Chem. 2024;31(22):3245-3264. doi: 10.2174/0929867331666230717154101.
5
Persistent Exhausted T-Cell Immunity after Severe COVID-19: 6-Month Evaluation in a Prospective Observational Study.重症 COVID-19 后持续存在的耗竭性 T 细胞免疫：一项前瞻性观察研究的 6 个月评估
J Clin Med. 2023 May 18;12(10):3539. doi: 10.3390/jcm12103539.
6
Knowledge Mapping of Drug Repositioning's Theme and Development.药物重定位主题与发展的知识图谱。
Drug Des Devel Ther. 2023 Apr 18;17:1157-1174. doi: 10.2147/DDDT.S405906. eCollection 2023.
7
An overview on the treatments and prevention against COVID-19.关于 COVID-19 的治疗和预防概述。
Virol J. 2023 Feb 8;20(1):23. doi: 10.1186/s12985-023-01973-9.
8
Highly sensitive electrochemical sensor based on carbon paste electrode modified with graphene nanoribbon-CoFeO@NiO and ionic liquid for azithromycin antibiotic monitoring in biological and pharmaceutical samples.基于石墨烯纳米带-CoFeO@NiO修饰碳糊电极和离子液体的高灵敏度电化学传感器用于生物和药物样品中阿奇霉素抗生素的监测。
Appl Nanosci. 2023 Jan 24:1-10. doi: 10.1007/s13204-023-02773-x.
9
An Improvement in the Antimicrobial Resistance Patterns of Urinary Isolates in the Out-Of-Hospital Setting following Decreased Community Use of Antibiotics during the COVID-19 Pandemic.在新冠疫情期间社区抗生素使用减少后，院外环境中尿液分离株的抗菌药物耐药模式有所改善。
Antibiotics (Basel). 2023 Jan 9;12(1):126. doi: 10.3390/antibiotics12010126.
10
Consequences of COVID-19 on the cardiovascular and renal systems.新型冠状病毒肺炎对心血管系统和肾脏系统的影响。
Sleep Med. 2022 Dec;100:31-38. doi: 10.1016/j.sleep.2022.07.011. Epub 2022 Aug 3.
本文引用的文献
1
Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.参考研究：《羟氯喹和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果》
Int J Antimicrob Agents. 2021 Jan;57(1):106176. doi: 10.1016/j.ijantimicag.2020.106176.
2
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.法国马赛接受羟氯喹/阿奇霉素和其他方案治疗的 3737 例 COVID-19 患者的结局：一项回顾性分析。
Travel Med Infect Dis. 2020 Jul-Aug;36:101791. doi: 10.1016/j.tmaid.2020.101791. Epub 2020 Jun 25.
3
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
Zotero 插件